O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol 2010; 105(1): 14–32; quiz 33.
McCullough AJ, O’Shea RS, Dasarathy S. Diagnosis and management of alcoholic liver disease. J Dig Dis 2011; 12(4): 257–262.
Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36(3): 242–252.
Rongey C, Kaplowitz N. Current concepts and controversies in the treatment of alcoholic hepatitis. World J Gastroenterol 2006; 12(43): 6909–6921.
Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol 2007; 41(8): 761–772.
Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155(4): 323–331.
Khan KN, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. Alcohol Alcohol 2000; 35(3): 286–295.
Monto A, Patel K, Bostrom A et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004; 39(3): 826–834.
Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1): S87–S96.
Chen CM, Yoon YH, Yi HY, Lucas DL. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. Alcohol Clin Exp Res 2007; 31(2): 285–292.
Tsui JI, Pletcher MJ, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. J Hepatol 2006; 44(2): 262–266.
Kim WR, Gross JB Jr, Poterucha JJ, Locke GR 3rd, Dickson ER. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology 2001; 33(1): 201–206.
Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998; 27(4): 914–919.
Novo-Veleiro I, Calle Cde L, Dominguez- Quiben S, Pastor I, Marcos M, Laso FJ. Prevalence of hepatitis C virus infection in alcoholic patients: cohort study and systematic review. Alcohol Alcohol 2013; 48(5): 564–569.
Fong TL, Kanel GC, Conrad A, Valinluck B, Charboneau F, Adkins RH. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology 1994; 19(3): 554–557.
Singal AK, Kuo YF, Anand BS. Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality. Eur J Gastroenterol Hepatol 2012; 24 (10): 1178–1184.
Singal AK, Sagi S, Kuo YF, Weinman S. Impact of hepatitis C virus infection on the course and outcome of patients with acute alcoholic hepatitis. Eur J Gastroenterol Hepatol 2011; 23(3): 204–209.
Mendenhall CL, Seeff L, Diehl AM et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). Hepatology 1991; 1: 581–589.
Nishiguchi S, Kuroki T, Yabusako T et al. Detection of hepatitis C virus antibodies and hepatitis C virus RNA in patients with alcoholic liver disease. Hepatology 1991; 14(6): 985–989.
Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol 2011; 45(8): 714–719.
Yokoyama H, Ishii H, Moriya S et al. Relationship between hepatitis C virus subtypes and clinical features of liver disease seen in alcoholics. J Hepatol 1995; 22(2): 130–134.
Rosman AS, Paronetto F, Galvin K, Williams RJ, Lieber CS. Hepatitis C virus antibody in alcoholic patients. Association with the presence of portal and/or lobular hepatitis. Arch Intern Med 1993; 153(8): 965–969.
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144(10): 705–714.
Yang AL, Vadhavkar S, Singh G, Omary MB. Epidemiology of alcohol-related liver and pancreatic disease in the United States. Arch Intern Med 2008; 168(6): 649–656.
Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005; 3(11): 1150–1159.
Pessione F, Ramond MJ, Peters L et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23(1): 45–53.
Schiff ER. Hepatitis C and alcohol. Hepatology 1997; 26(3 Suppl 1): 39S–42S.
Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S. Hepatitis C infection and alcohol use: a dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res 2006; 30(4): 709–719.
Kulkarni K, Tran T, Medrano M, Yoffe B, Goodgame R. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 2004; 38(5): 453–459.
Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360(26): 2758–2769.
Mathurin P, O’Grady J, Carithers RL et al. Corticosteroids improve shortterm survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60(2): 255–260.
Dunn W, Jamil LH, Brown LS et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41(2): 353–358.
Forrest EH, Evans CD, Stewart S et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54(8): 1174–1179.
Dominguez M, Rincon D, Abraldes JG et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008; 103(11): 2747–2756.
Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis–a randomised clinical trial. J Hepatol 2006; 44(4): 784–790.
Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005; 42(5): 700–706.
Verma S, Ajudia K, Mendler M, Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006; 51(9): 1637–1643.
Cabre E, Rodriguez-Iglesias P, Caballeria J et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32 (1): 36–42.
Louvet A, Naveau S, Abdelnour M et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45 (6): 1348–1354.
Ramond MJ, Poynard T, Rueff B et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326(8): 507–512.
Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119(6): 1637–1648.
Mathurin P, Moreno C, Samuel D et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365(19): 1790–1800.
Singal AK, Bashar H, Anand BS, Jampana SC, Singal V, Kuo YF. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology 2012; 55(5): 1398–1405.
Tome S, Martinez-Rey C, Gonzalez-Quintela A et al. Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. J Hepatol 2002; 36(6): 793–798.
Jampana SC, Khan R. Pathogenesis of alcoholic hepatitis: role of inflammatory signaling and oxidative stress. World J Hepatol 2011; 3(5): 114–117.
Hanck C, Rossol S, Bocker U, Tokus M, Singer MV. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol 1998; 33(6): 606–608.
von Baehr V, Docke WD, Plauth M et al. Mechanisms of endotoxin tolerance in patients with alcoholic liver cirrhosis: role of interleukin 10, interleukin 1 receptor antagonist, and soluble tumour necrosis factor receptors as well as effector cell desensitisation. Gut 2000; 47(2): 281–287.
Parlesak A, Schafer C, Schutz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000; 32(5): 742–747.
Bala S, Marcos M, Gattu A, Catalano D, Szabo G. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS ONE 2014; 9(5): e96864.
Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis 2010; 28(6): 737–744.
Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18(2): 353–372.
Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and nonalcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991; 12(2): 162–169.
Vlachogiannakos J, Saveriadis AS, Viazis N et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009; 29(9): 992–999.
Petrasek J, Bala S, Csak T et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012; 122(10): 3476–3489.
Jalan R, Gines P, Olson JC et al. Acute-on chronic liver failure. J Hepatol 2012; 57(6): 1336–1348.
Mookerjee RP, Stadlbauer V, Lidder S et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007; 46(3): 831–840.
Mandrekar P, Catalano D, Dolganiuc A, Kodys K, Szabo G. Inhibition of myeloid dendritic cell accessory cell function and induction of T cell anergy by alcohol correlates with decreased IL-12 production. J Immunol 2004; 173(5): 3398–3407.
Schiff ER, Ozden N. Hepatitis C and alcohol. Alcohol Res Health 2003; 27(3): 232–239.
Oshita M, Hayashi N, Kasahara A et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20(5): 1115–1120.
Siu L, Foont J, Wands JR. Hepatitis C virus and alcohol. Semin Liver Dis 2009; 29(2): 188–199.
Pang M, Bala S, Kodys K, Catalano D, Szabo G. Inhibition of TLR8- and TLR4-induced Type I IFN induction by alcohol is different from its effects on inflammatory cytokine production in monocytes. BMC Immunol 2011; 12: 55.
Liu BS, Janssen HL, Boonstra A. Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12. Eur J Immunol 2012; 42(9): 2431–2440.
Bala S, Tang A, Catalano D et al. Induction of Bcl-3 by acute binge alcohol results in toll-like receptor 4/LPS tolerance. J Leukoc Biol 2012; 92(3): 611–620.
Norkina O, Dolganiuc A, Catalano D et al. Acute alcohol intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 and STAT3 signaling in human monocytes. Alcohol Clin Exp Res 2008; 32(9): 1565–1573.
Szabo G, Dolganiuc A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology 2005; 210(2–4): 237–247.
Szabo G, Dolganiuc A, Mandrekar P, White B. Inhibition of antigen-presenting cell functions by alcohol: implications for hepatitis C virus infection. Alcohol 2004; 33(3): 241–249.
Dolganiuc A, Kodys K, Kopasz A, Marshall C, Mandrekar P, Szabo G. Additive inhibition of dendritic cell allostimulatory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction. Alcohol Clin Exp Res 2003; 27(6): 1023–1031.
Dolganiuc A, Oak S, Kodys K et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127(5): 1513–1524.
Safdar K, Schiff ER. Alcohol and hepatitis C. Semin Liver Dis 2004; 24(3): 305–315.
Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28(3): 805–809.
Cromie SL, Jenkins PJ, Bowden DS, Dudley FJ. Chronic hepatitis C: effect of alcohol on hepatic activity and viral titre. J Hepatol 1996; 25(6):821–826.
Kountouras J, Zavos C, Chatzopoulos D. Apoptosis in hepatitis C. J Viral Hepat 2003; 10(5): 335–342.
Fischer R, Baumert T, Blum HE. Hepatitis C virus infection and apoptosis. World J Gastroenterol 2007; 13(36): 4865–4872.
Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev 2010; 90(3): 1165–1194.
McCartney EM, Semendric L, Helbig KJ et al. Alcohol metabolism increases the replication of hepatitis C virus and attenuates the antiviral action of interferon. J Infect Dis 2008; 198(12): 1766–1775.
Bukong TN, Hou W, Kodys K, Szabo G. Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology 2013; 57(1): 70–80.
Hou W, Bukong TN, Kodys K, Szabo G. Alcohol facilitates HCV RNA replication via up-regulation of miR-122 expression and inhibition of cyclin G1 in human hepatoma cells. Alcohol Clin Exp Res 2013; 37(4): 599–608.
Pessione F, Degos F, Marcellin P et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27(6): 1717–1722.
Anand BS, Thornby J. Alcohol has no effect on hepatitis C virus replication: a meta-analysis. Gut 2005; 54(10): 1468–1472.
Chang J, Nicolas E, Marks D et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1(2): 106–113.
Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12(9): 735–739.
Wang K, Zhang S, Marzolf B et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009; 106(11): 4402–4407.
Laterza OF, Scott MG, Garrett-Engele PW, Korenblat KM, Lockwood CM. Circulating miR-122 as a potential biomarker of liver disease. Biomark Med 2013; 7(2): 205–210.
van der Meer AJ, Farid WR, Sonneveld MJ et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat 2013; 20(3): 158–166.
Bala S, Szabo G. MicroRNA signature in alcoholic liver disease. Int J Hepatol 2012; 2012: 498232.
Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013; 10(9): 542–552.
Su TH, Liu CH, Liu CJ et al. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci U S A 2013; 110(19): 7844–7849.
Cirera I, Bauer TM, Navasa M et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34(1): 32–37.
Lin RS, Lee FY, Lee SD et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophaegeal varices, and hyperdynamic circulation. J Hepatol 1995; 22(2): 165–172.
Moreau R, Jalan R, Gines P et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144(7): 1426–1437, 1437.e1–9.
Katoonizadeh A, Laleman W, Verslype C et al. Early features of acuteon-chronic alcoholic liver failure: a prospective cohort study. Gut 2010; 59(11): 1561–1569.
Duseja A, Chawla YK, Dhiman RK, Kumar A, Choudhary N, Taneja S. Non-hepatic insults are common acute precipitants in patients with acute on chronic liver failure (ACLF). Dig Dis Sci 2010; 55(11): 3188–3192.
Sen S, Davies NA, Mookerjee RP et al. Pathophysiological effects of albumin dialysis in acute-onchronic liver failure: a randomized controlled study. Liver Transpl 2004; 10(9): 1109–1119.
Wasmuth HE, Kunz D, Yagmur E et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis. J Hepatol 2005; 42(2): 195–201.